An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink
- PMID: 19486957
- DOI: 10.1016/j.vaccine.2009.05.036
An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink
Abstract
Using a new sequential analytic method, the safety of tetanus-diphtheria-acellular pertussis (Tdap) vaccine was monitored weekly among subjects aged 10-64 years during 2005-2008. Encephalopathy-encephalitis-meningitis, paralytic syndromes, seizures, cranial nerve disorders, and Guillain-Barré syndrome were selected as outcomes based on previous reports and biologic plausibility. The risk following Tdap was not significantly higher than the risk after Td. Statistical power was sufficient to detect a relative risk of 4-5 for Guillain-Barré syndrome and 1.5-2 for the other outcomes. This study provides reassurance that Tdap is similar in safety to Td regarding the outcomes studied and supports the viability of sequential analysis for post-licensure vaccine safety monitoring.
Similar articles
-
Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):921-925. doi: 10.1002/pds.4569. Epub 2018 Jun 3. Pharmacoepidemiol Drug Saf. 2018. PMID: 29862604 Free PMC article.
-
U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.Vaccine. 2013 Feb 27;31(10):1447-52. doi: 10.1016/j.vaccine.2012.10.097. Epub 2012 Nov 8. Vaccine. 2013. PMID: 23142308
-
A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.Pediatrics. 2008 Dec;122(6):e1179-85. doi: 10.1542/peds.2008-1977. Pediatrics. 2008. PMID: 19047220
-
Rationale for use of Tdap booster vaccines for adolescent immunization: overview of efficacy, safety, and clinical use.Clin Pediatr (Phila). 2006 Nov;45(9):785-94. doi: 10.1177/0009922806295276. Clin Pediatr (Phila). 2006. PMID: 17041165 Review.
-
Perspectives on the design and analysis of prelicensure trials: bridging the gap to postlicensure studies.Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S323-6. doi: 10.1086/322568. Clin Infect Dis. 2001. PMID: 11709767 Review.
Cited by
-
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000. Drugs. 2012. PMID: 22931522 Review.
-
Alpha spending for historical versus surveillance Poisson data with CMaxSPRT.Stat Med. 2019 May 30;38(12):2126-2138. doi: 10.1002/sim.8097. Epub 2019 Jan 28. Stat Med. 2019. PMID: 30689224 Free PMC article.
-
The "urban myth" of the association between neurological disorders and vaccinations.J Prev Med Hyg. 2015 Jun 10;56(1):E1-8. J Prev Med Hyg. 2015. PMID: 26789825 Free PMC article.
-
Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink's Rapid Cycle Analysis Capabilities.Pharmaceutics. 2013 Mar 12;5(1):168-78. doi: 10.3390/pharmaceutics5010168. Pharmaceutics. 2013. PMID: 24300403 Free PMC article.
-
Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):921-925. doi: 10.1002/pds.4569. Epub 2018 Jun 3. Pharmacoepidemiol Drug Saf. 2018. PMID: 29862604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical